The HelQ human DNA repair helicase utilizes a PWI-like domain for DNA loading through interaction with RPA, triggering DNA unwinding by the HelQ helicase core

Genome instability is a characteristic enabling factor for carcinogenesis. HelQ helicase is a component of human DNA maintenance systems that prevent or reverse genome instability arising during DNA replication. Here, we provide details of the molecular mechanisms that underpin HelQ function-its rec...

Full description

Saved in:
Bibliographic Details
Published inNAR cancer Vol. 3; no. 1; p. zcaa043
Main Authors Jenkins, Tabitha, Northall, Sarah J, Ptchelkine, Denis, Lever, Rebecca, Cubbon, Andrew, Betts, Hannah, Taresco, Vincenzo, Cooper, Christopher D O, McHugh, Peter J, Soultanas, Panos, Bolt, Edward L
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.03.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Genome instability is a characteristic enabling factor for carcinogenesis. HelQ helicase is a component of human DNA maintenance systems that prevent or reverse genome instability arising during DNA replication. Here, we provide details of the molecular mechanisms that underpin HelQ function-its recruitment onto ssDNA through interaction with replication protein A (RPA), and subsequent translocation of HelQ along ssDNA. We describe for the first time a functional role for the non-catalytic N-terminal region of HelQ, by identifying and characterizing its PWI-like domain. We present evidence that this domain of HelQ mediates interaction with RPA that orchestrates loading of the helicase domains onto ssDNA. Once HelQ is loaded onto the ssDNA, ATP-Mg binding in the catalytic site activates the helicase core and triggers translocation along ssDNA as a dimer. Furthermore, we identify HelQ-ssDNA interactions that are critical for the translocation mechanism. Our data are novel and detailed insights into the mechanisms of HelQ function relevant for understanding how human cells avoid genome instability provoking cancers, and also how cells can gain resistance to treatments that rely on DNA crosslinking agents.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.
ISSN:2632-8674
2632-8674
DOI:10.1093/narcan/zcaa043